Dasatinib Monohydrate CAS 863127-77-9 Dasatinib hydrate

Trade Term: FOB
Payment Terms: T/T,L/C,WU
skype
Trade on HiSupplier, Worry Free Guarantee
Trading safety, secure your money, lower the risk, protect both buyers and suppliers
HiSupplier is a Chinese multinational company in U.S, it helps to coordination and order landing.
More ›
  • Product Details
  • Company Profile
  • Product Reviews
Basic Info.
  • Brand: MOSINTER 
  • Name: Dasatinib Monohydrate 
  • CAS: 863127-77-9 
  • Molecular Formula: C22H28ClN7O3S 
  • Melting Point: Anti-cancer apis intermediate 
  • Molecular Weight: 506.02082 
  • Appearance: white powder 
  • Storage condition: Dasatinib hydrate 
  • Use: Vomiting chemotherapy drug treatment 
  • Alias: MK-0869 
  • Model No.: MOS 29 
  • Place of Origin: Zhejiang  
  • Min.Order: 100 Gram
  • Means of Transport: Ocean, Air, Land
Supply Capacity
  • Production Capacity: 3 Ton/Year
  • Packing:According to the request of customer
  • Delivery Date: within 7 days

Dasatinib Monohydrate CAS 863127-77-9 used to have treatment the people of drug resistance or chronic myelogenous leukemia can't tolerate all disease duration.


white powder


Dasatinib Monohydrate

Synonyms: dasatinib monohydrate;n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate;n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;Dasatinib(TINIBS);N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate;Dastinib;Bms 35482503;Dasatinib hydrate

25KG drum


Dasatinib is a tyrosine kinase inhibitors, the main is based on four international from total included 911 patients, multicenter phase Ⅱ test the safety and efficacy of results and other supporting data and approved for use in the above two indications. It is the most commonly reported side effects in clinical research have fluid retention, gastrointestinal symptoms and bleeding events, etc.; The most frequently reported serious side effects is calorific, pleural effusion, febrile neutral white) used in myeloid leukemia.

package: 25KG Drum or According to the request of customer



Dasatinib is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in patients withchronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.


In a Phase I dose escalation study published in June 2006, dasatinib was tested in patients who were resistant to or who could not tolerateimatinib. Complete hematological responses were seen in 37 of 40 patients with chronic-phase CML. Major hematologic responses were seen in 31 of 44 patients with accelerated-phase CML, CML in blast crisis, or Ph+ ALL.


Responses were maintained in 95% of patients with chronic-phase CML, with a median follow-up time of >12 months. In patients with accelerated-phase CML, 82% remained in remission, although with a median follow-up of only 5 months. Nearly all patients with CML in blast crisis or Ph+ ALL relapsed within 6 months.


Neutropenia and myelosuppression were common toxic effects. Fifteen patients (of 84, i.e. 18%) in the above-mentioned study developed pleural effusions, which were felt to be a side effect of dasatinib. Some of these patients required thoracentesis or pleurodesis to treat the effusions. Other adverse events included mild to moderate diarrhea, peripheral edema, and headache. A small number of patients developed abnormal liver function tests which returned to normal without dose adjustments. Mild hypocalcemia was also noted, but did not appear to cause any significant problems. Several cases of pulmonary arterial hypertension (PAH) were found in patients treated with dasatinib.

On October 11, 2011 the U.S. Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH). Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs). In reported cases, patients developed PAH after starting dasatinib, including after more than one year of treatment.

Information about this risk has been added to the Warnings and Precautions section of the Sprycel drug label.




Send message to this supplier
Mr. Fedor
Tel: +86-574-89212210
Mobile: +86-18989305995
Enter between 20 to 3,000 chatacters.
Contact Method
MOSINTER GROUP LIMITED
Guangbo Center Office 2001, YinXianDaDao 1357, Ningbo, Zhejiang, China (Mainland) / 315100
Fax: +86-574-89212215
Didn't find what you're looking for? Post Buying Lead or contact our customer service specialist for help!
Buyer Help Center